What is Dyadic Applied BioSolutions?
Dyadic International, operating as Dyadic Applied BioSolutions, is a global biotechnology firm established in 1979. The company specializes in developing and manufacturing low-cost proteins for biologic vaccines and drugs through its proprietary Thermothelomyces heterothallica-based C1 gene expression platform. This innovative fungal expression system is designed to expedite the development timeline, reduce production expenses, and enhance the performance of a wide array of therapeutic products, including virus-like particles, antigens, and monoclonal antibodies. Dyadic's business model centers on research and development collaborations and licensing agreements, aiming to efficiently bring biologic products to market and improve healthcare accessibility.
How much funding has Dyadic Applied BioSolutions raised?
Dyadic Applied BioSolutions has raised a total of $150K across 1 funding round:
Debt
$150K
Debt (2020): $150K with participation from PPP
Key Investors in Dyadic Applied BioSolutions
PPP
Public-Private Partnership
What's next for Dyadic Applied BioSolutions?
With its large-scale, late-stage funding, Dyadic Applied BioSolutions is poised for significant expansion. The recent strategic investment signals strong confidence from stakeholders in the company's C1 platform and its potential to disrupt biopharmaceutical manufacturing. Future developments are likely to focus on scaling production capabilities, forging new strategic partnerships, and advancing its pipeline of therapeutic products. This capital infusion will be critical in navigating the complex regulatory landscape and accelerating the commercialization of its innovative protein-based solutions, solidifying its position as a key player in the biopharma industry.
See full Dyadic Applied BioSolutions company page
